Publisher Login
Manuscript Statistics
1
2025-12-12 | Browse: 10 | Download: 0
2
2025-12-12 | Browse: 12 | Download: 0
3
4
5
6
7
8
9
10
2025-12-12 | Browse: 10 | Download: 0
11
12
13
2025-12-12 | Browse: 9 | Download: 0
14
15
16
17
18
19
20
875 items Read more >>
1
"The submission process to the WJG was satisfactory and well structured. The online submission system was intuitive and user-friendly, ..."
[Read more]
"The submission process to the WJG was satisfactory and well structured. The online submission system was intuitive and user-friendly, allowing for a smooth upload of manuscript files and supplementary materials. Editorial communications were timely, clear, and professional, providing transparent guidance at each stage of the review process. Overall, the experience was efficient and well organized. "
[Collapse]
Paratore M, Miliani S, D’Acunzo G, Viceconti N, Andaloro S, Cerniglia G, Mancuso F, Melita E, Rizzatti G, Gasbarrini A, Riccardi L, Garcovich M. Advances in endoscopic ultrasound-guided shear wave elastography: A comprehensive review of its clinical applications. World J Gastroenterol 2025; 31(46): 113585
2
"In this review, we systematically examine the transformative applications and ongoing challenges of artificial intelligence (AI) in ..."
[Read more]
"In this review, we systematically examine the transformative applications and ongoing challenges of artificial intelligence (AI) in the diagnosis and management of liver diseases. We believe AI is reshaping hepatology—moving the field from experience-based decision-making toward data-driven precision medicine. Our central argument is that AI has demonstrated high diagnostic performance in liver fibrosis staging, early hepatocellular carcinoma detection, and non-alcoholic fatty liver disease risk stratification (e.g., deep learning models using CT/MRI have reported AUCs up to 0.89–0.92), and can further integrate multi-omics and clinical data to build individualized prognostic models. However, clinical translation remains hindered by several critical barriers: data heterogeneity, algorithmic bias, insufficient model interpretability, lack of real-time integration into clinical workflows, and the absence of harmonized regulatory frameworks. We particularly emphasize that future progress must focus on the following directions: 1.Promoting multi‑center, prospective, and multi‑ethnic validation to ensure model generalizability and fairness. 2.Adopting privacy‑preserving computing techniques (e.g., federated learning) to enable cross‑institutional collaboration without compromising data security. 3.Deepening the integration of explainable AI (XAI) with clinical decision scenarios through visual interpretations (e.g., attention heatmaps) to build clinician trust. 4.Establishing “clinician‑in‑the‑loop” design and evaluation frameworks to ensure AI tools align with real clinical needs and workflows. We envision AI not as a replacement for physicians, but as a “clinical collaborator” that empowers earlier intervention, personalized therapy, and optimized healthcare resources. Realizing this vision will require continued collaboration among hepatologists, data scientists, policymakers, and patients—striking a balance between innovation and rigor. "
[Collapse]
Sun JR, Sun XN, Lu BJ, Deng BC. Artificial intelligence in hepatopathy diagnosis and treatment: Big data analytics, deep learning, and clinical prediction models. World J Gastroenterol 2025; 31(45): 111176
3
"I appreciate the transparent, anonymous, and rigorous peer-review process employed by the World Journal of Gastrointestinal Oncology. ..."
[Read more]
"I appreciate the transparent, anonymous, and rigorous peer-review process employed by the World Journal of Gastrointestinal Oncology. The reviewers provided fair, constructive, and scientifically focused feedback that substantially improved the clarity, scientific rigor, and overall quality of my manuscript. I also commend the editorial team for their efficiency, professionalism, and smooth handling of the publication process. "
[Collapse]
Alharbi SR. Tumor calcification and sustained complete response after chemoembolization in hepatocellular carcinoma: Two case reports and review of literature. World J Gastrointest Oncol 2025; 17(12): 113341
4
"I am extremely satisfied with the publication experience at this journal. The editorial team was professional and responsive, providing ..."
[Read more]
"I am extremely satisfied with the publication experience at this journal. The editorial team was professional and responsive, providing clear, constructive peer reviews that refined my research. The submission system was user-friendly, and the publication timeline was efficient and transparent. I highly recommend this journal to fellow scholars and look forward to future collaborations. "
[Collapse]
Meng XY, Cai YM, Sun NN, Zhang WH, Cui RX, Zhang L, Zheng CC, Sun Z, Luo WX, Wang FW. Preliminary exploration of programmed death 1 inhibitor combined with fruquintinib and docetaxel for advanced colorectal cancer. World J Gastrointest Oncol 2025; 17(12): 112548
5
"Thank you very much for your thorough, constructive and encouraging peer-review work; your expert comments, detailed suggestions and ..."
[Read more]
"Thank you very much for your thorough, constructive and encouraging peer-review work; your expert comments, detailed suggestions and generous guidance have significantly sharpened our research question of the manuscript, and will undoubtedly benefit future readers. We are also sincerely satisfied with the intuitive, efficient and reliable online submission system, whose instant status updates, seamless file-upload interface and rapid response times made the entire submission and revision process remarkably smooth and stress-free. "
[Collapse]
Li X, Hao XX, Zhu RQ, Zhou HW. Molecular mechanism of non-coding RNAs-mediated radiosensitivity regulation in colorectal cancer. World J Gastrointest Oncol 2025; 17(12): 113636
6
"Excellent editing and reviewing process during this manuscript submission. Keep up the great work and progress to great works and ..."
[Read more]
"Excellent editing and reviewing process during this manuscript submission. Keep up the great work and progress to great works and managing of manuscripts to high novel level. Big congratulations for excellent and exquisite works. I will promoting to my other colleagues and keep submitting to F6 publishing in future with others manuscripts. "
[Collapse]
Koo TH, Leong XB, Lee YL, Hayati F, Zakaria AD. Interlaced roles of mitochondrial DNA in colorectal cancer: Liquid-biopsy biomarkers, nuclear mtDNA-driven genomic instability, and mito-encoded micro peptide signaling. World J Gastrointest Oncol 2025; 17(12): 112753
7
"Good peer-review process. It was slightly difficult to navigate the online platform and the peer review took longer than expected ..."
[Read more]
"Good peer-review process. It was slightly difficult to navigate the online platform and the peer review took longer than expected (it was particularly difficult to communicate with the editors at certain points). Overall the process ran smoothly however and I would recommend others to consider this journal when submitting a manuscript. "
[Collapse]
Ahmadi S, Joarder I, Jowhari F. Beyond the skin - metastatic basal cell carcinoma in the stomach: A case report. World J Gastroenterol 2025; 31(46): 112010
8
"Takes too long to be visible on pubmed and also the 50 word rule is not apt as some authors may want to comment short. Takes too long ..."
[Read more]
"Takes too long to be visible on pubmed and also the 50 word rule is not apt as some authors may want to comment short. Takes too long to be visible on pubmed and also the 50 word rule is not apt as some authors may want to comment short. Takes too long to be visible on pubmed and also the 50 word rule is not apt as some authors may want to comment short. "
[Collapse]
Zhou AL, Chiang JYH, Chan KS, Tan N, Shelat VG. Decoding Alexander the Great’s gastrointestinal cause of death using artificial wisdom: An artificial intelligence-human inquiry into a medical mystery. World J Gastroenterol 2025; 31(46): 111669
9
"All authors would like to express their gratitude to the reviewers of this thesis for their professional review comments, the ..."
[Read more]
"All authors would like to express their gratitude to the reviewers of this thesis for their professional review comments, the modifications suggested by the reviewers are very helpful in improving the quality of this thesis; and to the editorial board for their professional editorial comments, and for their hard work and selflessness. "
[Collapse]
Kang LM, He XL, Lang L, Wang AY, Wang X, Liu YH, Zhao YH, Xu L, Yu FK, Zhang FW. Safety and efficacy of cryoablation in treating locally advanced pancreatic cancer. World J Gastrointest Oncol 2025; 17(12): 113387
10
"The manuscript editing and publishing process was seamless, efficient, and transparent. The improvement of figure quality and timely ..."
[Read more]
"The manuscript editing and publishing process was seamless, efficient, and transparent. The improvement of figure quality and timely updates on the status of manuscript is highly appreciated. The production quality of the published article is good. Overall, the authors are satisfied with the positive experience of manuscript editing and publishing process. "
[Collapse]
Shamsad A, Gautam T, Singh R, Banerjee M. CD36 fatty-acid-transporter gene variants-CD36 G/A (rs1761667) and CD36 C/T (rs75326924) as biomarkers for risk-prediction in gestational diabetes mellitus. World J Biol Chem 2025; 16(4): 111104
11
"The manuscript submission system is extremely user-friendly. The comments provided by the editors and reviewers are highly professional ..."
[Read more]
"The manuscript submission system is extremely user-friendly. The comments provided by the editors and reviewers are highly professional and insightful, which have significantly improved the quality of this manuscript. If we have relevant and suitable manuscripts in the future, we would be very willing to submit them to World Journal of Gastrointestinal Oncology. "
[Collapse]
Lyu H, Chen JS, Tang JF, Zhou CF. miR-136: A biomarker in the inflammation-cancer transformation of gastric cancer. World J Gastrointest Oncol 2025; 17(12): 114173
12
"all every nice! The magazine has fast efficiency in selling articles, timely feedback to authors, and is serious and responsible; ..."
[Read more]
"all every nice! The magazine has fast efficiency in selling articles, timely feedback to authors, and is serious and responsible; At the same time, I hope to improve my level of writing papers and that the magazine will continue to thrive, benefiting the majority of authors! Thank you to the editor for editing and guiding this article, and also thank all authors for their contributions to the article! I hope there will be opportunities for mutual cooperation in the future! "
[Collapse]
Jin Y, Xiao YS, Zhou P. Prospective study on the impact of parental anxiety on academic performance in children with attention deficit. World J Psychiatry 2025; 15(12): 111663
13
"WJGO stands out as a valuable journal for professionals engaged in gastrointestinal oncology. Its content is both clinically relevant ..."
[Read more]
"WJGO stands out as a valuable journal for professionals engaged in gastrointestinal oncology. Its content is both clinically relevant and scientifically rigorous, focusing on translating cutting-edge research into actionable insights for clinical practice. The journal covers a wide spectrum of topics that address the unmet needs of the field. WJGO enables efficient knowledge acquisition, making it a go-to reference for staying updated on the latest developments in gastrointestinal oncology research and clinical care. "
[Collapse]
Zhang XL, Zhang JY, Xie L, Li H, Wang L. Advanced gastric small cell carcinoma with immunotherapy-based treatment: A case report. World J Gastrointest Oncol 2025; 17(12): 114390
14
"I sincerely thank the Editorial Board of the World Journal of Hepatology for the kind invitation to submit this review and for the ..."
[Read more]
"I sincerely thank the Editorial Board of the World Journal of Hepatology for the kind invitation to submit this review and for the opportunity to contribute to the journal. I appreciate the professional handling of the manuscript and the efficient editorial process. It is an honor to have our work published in the World Journal of Hepatology, and we look forward to future opportunities for collaboration. "
[Collapse]
Abdalla MMI, Ismail-Khan M. Liver as a metabolic sensor in gestational diabetes: Implications for offspring’s liver and diabetes risk. World J Hepatol 2025; 17(11): 110185
15
"I would like to express my sincere appreciation to the editorial team and reviewers for their excellent handling of our manuscript. ..."
[Read more]
"I would like to express my sincere appreciation to the editorial team and reviewers for their excellent handling of our manuscript. The journal’s submission and review process was remarkably streamlined, efficient, and transparent, which greatly facilitated timely revisions and improved the overall quality of our work. Overall the experience has been highly positive, and I commend the editorial office for maintaining such a well-organized and author-friendly workflow. It has been a pleasure to contribute to the journal. "
[Collapse]
Mehta R, Patel A, Vyas B, Desai B, Adhvaryu D, Sojitra P, Bhuptani S. L-arginine-induced chronic pancreatitis in mice: Evaluating effects of pirfenidone and simvastatin. World J Gastrointest Pharmacol Ther 2025; 16(4): 111977
16
"I would like to express my gratitude to all the teachers in the editorial department for their support and assistance. Your journal ..."
[Read more]
"I would like to express my gratitude to all the teachers in the editorial department for their support and assistance. Your journal has a fast review process and the review comments are very fair and helpful in improving the quality of the manuscripts. If there are any more manuscripts, I plan to continue submitting them to your publication. "
[Collapse]
Pan J, Li P, Zhou YH, Pan TT, Chen YT, Chu XY. Long-term survival after treatment of gastric cancer with S-1 plus oxaliplatin regimen and sintilimab: A case report. World J Gastrointest Oncol 2025; 17(12): 112853
17
"Thanks to the reviewers, editors, and all staff members for their help. I am honored to have my manuscript published in this journal ..."
[Read more]
"Thanks to the reviewers, editors, and all staff members for their help. I am honored to have my manuscript published in this journal and the journal has been very helpful.The reviewers' comments helped me a lot.The editor also helped me in formatting the manuscript in a very standardized way. I hope the high level of work will continue. "
[Collapse]
Wang CY, Ma L, Zhao Y, Zhang XJ, Li S, Liu YG, Guo HM, Qi JG, Wang JQ, Ye WX, Li JZ, Zhang T. Clinical characteristics of colorectal polyps in patients with non-alcoholic fatty liver disease in high altitude areas. World J Gastrointest Oncol 2025; 17(12): 112761
18
"I was very satisfied with the overall experience of submitting and publishing my manuscript in this journal. The online submission ..."
[Read more]
"I was very satisfied with the overall experience of submitting and publishing my manuscript in this journal. The online submission system was clear and easy to use, and all editorial communications were timely and transparent. The peer review reports were constructive, detailed, and clearly aimed at improving the scientific quality of the article. The copy-editing, figure and table preparation, and final PDF and online versions were handled professionally and accurately. Overall, I consider the editorial and production process to be efficient, fair, and author-friendly, and I would be pleased to submit further work to this journal in the future. "
[Collapse]
Abdelhamed W, El-Kassas M. Endo-hepatology: Bridging the gap between lumen and liver. World J Gastroenterol 2025; 31(46): 113145
19
"I would like to express my appreciation for the overall submission and peer review experience with WJGPT. The process was clear, well ..."
[Read more]
"I would like to express my appreciation for the overall submission and peer review experience with WJGPT. The process was clear, well organized, and professionally managed from start to finish. I am also very grateful for the thoughtful and constructive comments provided by the reviewers. Their insights helped strengthen the manuscript and highlighted important aspects that improved the overall clarity and scientific rigor of the work. Although my experience was very positive, I would like to respectfully share a few suggestions that might further improve the workflow. In particular, streamlining steps such as CLA collection, the numerous supporting document requirements, and editorial communication after acceptance. Additionally, I found the limit set for self-references challenging, especially in the context of rare diseases. Overall, I sincerely appreciate the professionalism and dedication demonstrated by the editorial and review teams. Thank you for your commitment to maintaining a high-quality and fair peer review process. I look forward to the possibility of working with the journal again in the future. "
[Collapse]
Solar Muñiz H, Fernández A, Busoni V, Martínez MI, Rumbo C, De Barrio S, Saure C, Balacco M, Buncuga MG, Dlugoszweski C, Manzur A, Rudi L, Matoso MD, Cosentino S, Ussher F, Manzur F, Demarchi J, Malaver E, Brion L, Ungar L. Real-world effectiveness and safety of teduglutide in adult and pediatric patients with short bowel syndrome in Argentina. World J Gastrointest Pharmacol Ther 2025; 16(4): 110642
20
"We extend our sincere gratitude to the editorial team of The World Journal of Gastrointestinal Oncology for their efficient and ..."
[Read more]
"We extend our sincere gratitude to the editorial team of The World Journal of Gastrointestinal Oncology for their efficient and professional process management. From submission to acceptance, the timely feedback and clear guidance throughout the process fully demonstrate the journal's rigorous academic approach and commitment to service. The constructive feedback from both reviewers was invaluable. They not only pinpointed precise directions for refining research details but also offered insightful suggestions for extending the study's scope. Their professional insights provided crucial support for enhancing the paper's quality, from which I have gained profound benefits. "
[Collapse]
Huang LH, Fang YJ, Zheng XJ, Huang C, Li CL, Yu B, Huang MJ, Qin SJ, Huang DY, Lu DW. Application of multimodal fusion technology in early recurrence prediction and pathological analysis of hepatocellular carcinoma. World J Gastrointest Oncol 2025; 17(12): 114037
20194 items Read more >>
1
"This is a very interesting paper. I ask some questions for you.When comparing clip-E-CIGARETTES andEUS-C+G, the varicella obliteration ..."
[Read more]
"This is a very interesting paper. I ask some questions for you.When comparing clip-E-CIGARETTES andEUS-C+G, the varicella obliteration rate is 91.7% and 94.4%,respectively and rebleeding is 23.6% and 19.4%,respectively,suggesting that Clip-ECI has a slightly lower success rate.Please also consider Clip-ECI and EUS-C+G from the point of cost and procedure time.How do you deal with rebleeding cases after endoscopic procedure?Also ,please tell us about cases where endoscopic treatment is difficult."
[Collapse]
Giri S, Kumar K. Gastric varices management: Is clip-assisted glue injection a real-world alternative to endoscopic ultrasound-guided therapy? World J Gastroenterol 2025; 31(46): 114149
2
"In recent years, knowledge of the diagnostic and therapeutic roles of stem cells in many digestive system diseases has increased ..."
[Read more]
"In recent years, knowledge of the diagnostic and therapeutic roles of stem cells in many digestive system diseases has increased dramatically. Stem cells, with their inherent self-renewal and differentiation capabilities, can expand the therapeutic possibilities of modern gastroenterology across varied diagnostic and therapeutic fields. For example, as the authors of this review report, liver organoids derived from human pluripotent stem cells are used for diverse liver cancer remodeling and drug-sensitivity testing. Furthermore, mesenchymal stem cells/stromal cells are used in clinical/therapeutic studies for a large number of liver diseases. It is known that liver diseases (benign and malignant) result in high morbidity and mortality in all countries of the world. The financial burden on international health systems is becoming increasingly unsustainable in many countries, even in those that are highly developed economically. The implementation of stem cell-based diagnosis and treatment strategies for liver diseases is expected to become a reality in the near future, with visible consequences not only in the successful care of patients but also in improving healthcare economic parameters.
"
[Collapse]
Wang YX, Ren YN, Zhang SS, Sun S, Xu MY, Wei T, Zhang LS. Application of stem cells in the precise diagnosis and treatment of liver diseases. World J Gastroenterol 2025; 31(46): 114415
3
"1. This review presents a thorough and timely overview of stem cell-based strategies in the diagnosis, modeling and treatment of liver ..."
[Read more]
"1. This review presents a thorough and timely overview of stem cell-based strategies in the diagnosis, modeling and treatment of liver diseases. The authors have gathered an impressive volume of literature and have covered a wide spectrum of topics that range from pluripotent stem cell differentiation to organoid systems and clinical applications. One of the most notable strengths of the manuscript is the inclusion of clinical trial information, which has been organized into clear and informative tables that greatly enhance the translational relevance of the work. Although the content is comprehensive and highly informative, the overall narrative would benefit from more concise expression because certain sections contain repeated explanations and overly detailed descriptions that affect readability.
2. References：The manuscript contains a rich and extensive reference list, which reflects careful and comprehensive literature collection. This is a clear advantage of the review and provides the reader with broad and current coverage of relevant studies.
3. Language：The manuscript generally uses appropriate scientific terminology and conveys complex concepts accurately. However, the writing occasionally becomes verbose and repetitive. Several paragraphs contain long and heavily structured sentences, repeated connective phrases and extensive lists of factors or markers. These patterns interrupt the natural flow of the text and make some sections difficult to read. A more concise presentation of key ideas and smoother transitions between paragraphs would help strengthen the clarity and coherence of the manuscript. Reducing repeated descriptions of differentiation procedures, signaling pathways and mesenchymal stem cell mechanisms would particularly improve the overall fluency.
4. Figures and tables：The figures and tables play a helpful role in supporting the manuscript. The tables summarizing differentiation methods and clinical trials are especially informative and make complex information more accessible to readers. Some figures contain a large amount of condensed information and many abbreviations, which may make them difficult to interpret at a glance. However, the authors have provided all the abbreviations right next to each table, which is very good. In addition, figure 2 that integrates the major mechanisms and introduction of stem cell-based liver organoids is exquisite visually but may require further editing conceptually.
5. Caveats or drawbacks：
Although the review provides extensive information, it relies heavily on descriptive summaries and would benefit from deeper analytical discussion. Several important challenges are mentioned only briefly, such as heterogeneity among stem cell sources, safety considerations in clinical translation, variability of organoid systems and the limited outcomes of early clinical studies. A more thorough examination of these issues would give the review greater authority and balance.
Overall, the manuscript offers a rich collection of information and valuable resources, especially through its comprehensive references and clinical trial summaries. The quality of the paper would be further improved by tightening the language, and reducing redundancy.
I would like to comment a little bit more at the end of this ‘Track article quality’ section. The review appropriately highlights stem cell derived exosomes and extracellular vesicles, which is a valuable component of the manuscript. As far as current knowledge suggests, multiple clinical trials involving exosomes or other extracellular vesicle based therapeutics are actively underway. These vesicle based preparations may offer functional advantages comparable to their parental stem cells, while potentially avoiding several practical and safety related challenges associated with cell based therapies, including difficulties in storage, risks of uncontrolled proliferation, and concerns related to tumorigenesis. Given these advantages, a more extensive discussion of exosomes, extracellular vesicles, and their clinical development would further strengthen the manuscript. This topic may be an excellent focus for the authors to expand upon in their future work. Considering the comprehensive scope and overall quality of this review, I would also recommend it for recognition or award within the journal.
"
[Collapse]
Wang YX, Ren YN, Zhang SS, Sun S, Xu MY, Wei T, Zhang LS. Application of stem cells in the precise diagnosis and treatment of liver diseases. World J Gastroenterol 2025; 31(46): 114415
4
"The authors express concern about the lack of detailed analysis of the depth of analysis, i.e., tumor miss rates, machine learning ..."
[Read more]
"The authors express concern about the lack of detailed analysis of the depth of analysis, i.e., tumor miss rates, machine learning model complexity, and dataset quality. They also discuss future directions for the potential of AI in endoscopy training to facilitate skill development and improve the overall proficiency of endoscopists, a crucial area for the future adoption of AI in clinical practice. For AI endoscopy to further develop, we need to work on updating image data and deep learning."
[Collapse]
Fogas CR, Balassone V. Artificial intelligence in gastrointestinal endoscopy: Focus on analytical depth and endoscopist training. Artif Intell Gastrointest Endosc 2025; 6(4): 115140
5
"AI is an important milestone for future development in medicine and science. Nonetheless, there are many AI models and each model ..."
[Read more]
"AI is an important milestone for future development in medicine and science. Nonetheless, there are many AI models and each model has its own learning objectives. Incorporation of multiple AI models and training machine/ learning can greatly enhance the accuracy and readiness of using it to help in hepatopathy. Also, there are many hepatopathy and a systematic way to categories them will be a challenging act."
[Collapse]
Sun JR, Sun XN, Lu BJ, Deng BC. Artificial intelligence in hepatopathy diagnosis and treatment: Big data analytics, deep learning, and clinical prediction models. World J Gastroenterol 2025; 31(45): 111176
6
"The manuscript is written well. Its structure is appropriate for this type of article. Ethical approval form meets the requirements. ..."
[Read more]
"The manuscript is written well. Its structure is appropriate for this type of article. Ethical approval form meets the requirements. Methods are appropriate and effective. Results are appropriate of methods and are authentic. Tables and biostatistics data are perfect. The references are adequate of topic. Language of article is satisfied."
[Collapse]
Wu PE, Chen PJ, Su WC, Chang TK, Chen YC. Perforated sigmoid colon diverticulitis initially presenting with pneumoperitoneum, pneumoretroperitoneum, and pneumomediastinum: A case report. World J Clin Cases 2025; 13(34): 112593
7
"The manuscript is written well. Its structure is appropriate for this type of article. Ethical approval form meets the requirements. ..."
[Read more]
"The manuscript is written well. Its structure is appropriate for this type of article. Ethical approval form meets the requirements. Methods are appropriate and effective. Results are appropriate of methods and are authentic. Tables and biostatistics data are perfect. The references are adequate of topic. Language of article is satisfied."
[Collapse]
Deng X, Lv LY, Jiang SX, Huang JX, Chen XY, Zhang MF, Qi J, Yang M. Low-grade appendiceal mucinous neoplasm: A case report. World J Clin Cases 2025; 13(34): 111668
8
"With all due respect, this case shouldn't have been accepted for publication. I lacks complete originality and shows lots of ..."
[Read more]
"With all due respect, this case shouldn't have been accepted for publication. I lacks complete originality and shows lots of contradictions. That is, the title contradicts the case itself. Initially presenting with Pneumoperitoneum and the cases report indicates that the patient had "three (3) days" with lower abdominal pain. Irregardless of that, whatever clinical presentation, this case shows nothing new that has previously been reported. In conclusion this case report lacks complete originality."
[Collapse]
Wu PE, Chen PJ, Su WC, Chang TK, Chen YC. Perforated sigmoid colon diverticulitis initially presenting with pneumoperitoneum, pneumoretroperitoneum, and pneumomediastinum: A case report. World J Clin Cases 2025; 13(34): 112593
9
"First of all, congratulations on the publication of your paper. I have read it carefully, and I found it to be extremely well written, ..."
[Read more]
"First of all, congratulations on the publication of your paper. I have read it carefully, and I found it to be extremely well written, highly educational, and truly informative for readers. For these reasons, I would like to award this paper the first prize. I hope you will continue to produce such valuable work in the future. Thank you very much."
[Collapse]
Usuda D, Furukawa D, Imaizumi R, Ono R, Kaneoka Y, Nakajima E, Kato M, Sugawara Y, Shimizu R, Inami T, Kawai K, Matsubara S, Tanaka R, Suzuki M, Shimozawa S, Hotchi Y, Osugi I, Katou R, Ito S, Mishima K, Kondo A, Mizuno K, Takami H, Komatsu T, Nomura T, Sugita M. Recurrence of acyclovir-resistant herpes encephalitis in an immunocompromised patient: A case report. World J Clin Cases 2025; 13(34): 111438
10
"At the Baveno VII consensus workshop has defined the concept of recompensation of decompensated liver cirrhosis. It implies that after ..."
[Read more]
"At the Baveno VII consensus workshop has defined the concept of recompensation of decompensated liver cirrhosis. It implies that after elimination of the etiological factor, there is at least a partial regression of structural and functional disorders in the liver, reduction of portal pressure with a positive effect on portal hypertension related complications. Many studies have shown the efficacy of direct acting antivirals (DAAs) in achieving recompensation of HCV-related decompensated liver cirrhosis. The authors confirmed these data in Egyptian patients."
[Collapse]
Abdel Hafez RS, Semeya AA, Elgamal R, Othman AA. Direct-acting antiviral therapy reduces variceal rebleeding and improves liver function in hepatitis C virus-related cirrhosis: A multicenter retrospective cohort study. World J Hepatol 2025; 17(11): 110638
11
"This is a comprehensive and well-structured review that effectively synthesizes the complex landscape of MASLD in Egypt. The authors ..."
[Read more]
"This is a comprehensive and well-structured review that effectively synthesizes the complex landscape of MASLD in Egypt. The authors have articulated the convergence of risk factors, diagnostic challenges, and management gaps, positioning MASLD as a critical public health priority. The article's strength lies in its contextualization of the problem within Egypt's unique epidemiological and socioeconomic backdrop, particularly the interplay with the legacy of HCV and nutritional transitions. The inclusion of figures illustrating the multifactorial risks enhances the manuscript's clarity and impact.
There are several inherent challenges remain unresolved. The review points out that studies evaluating the prevalence of MASLD in Egypt are scarce and often include small numbers, and the prevalence and impact of key genetic variants (e.g., PNPLA3, TM6SF2) in the Egyptian population remain underexplored. The natural history and progression rates of MASLD specifically within the Egyptian population are not well-defined due to the absence of longitudinal cohort studies.
The authors have already laid out a roadmap for future research. They intend to advocate for and potentially lead large-scale, population-based epidemiological studies. The appropriate methodology like a stratified cluster sampling design, and the non-invasive diagnostics like FibroScan, could ensure the accuracy to assess the prevalence and fibrosis stages.
The review by Abdelhamed et al. is a powerful call to action, raising interest in non-communicable disease like MASLD in Egypt, and providing an evidence-based argument for a public health-oriented approach to a complex disease. "
[Collapse]
Abdelhamed W, Amin M, Waked I, El-Kassas M. Metabolic dysfunction-associated steatotic liver disease in Egypt: Epidemiology, risk factors and management challenges. World J Gastroenterol 2025; 31(45): 111643
12
"This manuscript showed the cellular mechanisms of pentadecanoic acid as an odd-number fatty acid. The presented figures are interesting ..."
[Read more]
"This manuscript showed the cellular mechanisms of pentadecanoic acid as an odd-number fatty acid. The presented figures are interesting and include valuable information, especially Figure 2, which shows the relation between pentadecanoic acid and cell signaling. In this figure, Mek/ERk and JAK/STAT pathways were shown as the pathways in which pentadecanoic acid was engaged."
[Collapse]
Mercola J. Molecular and cellular mechanisms of pentadecanoic acid. World J Biol Chem 2025; 16(4): 111258
13
"This manuscript showed biomarkers for Gestational diabetes mellitus, which is an important metabolic disorder in pregnancy. The authors ..."
[Read more]
"This manuscript showed biomarkers for Gestational diabetes mellitus, which is an important metabolic disorder in pregnancy. The authors have shown the biochemical parameters of the healthy and diabetic participants. This is a good point. The authors also showed a good agarose electrophoresis of PCR products. In addition, the gene expression of gene variants was studied and proved as biomarkers of
Gestational diabetes mellitus.
"
[Collapse]
Shamsad A, Gautam T, Singh R, Banerjee M. CD36 fatty-acid-transporter gene variants-CD36 G/A (rs1761667) and CD36 C/T (rs75326924) as biomarkers for risk-prediction in gestational diabetes mellitus. World J Biol Chem 2025; 16(4): 111104
14
"Laparoscopic hepatectomy is a minimally invasive surgical procedure to remove part of the liver in cases of benign and/or malignant ..."
[Read more]
"Laparoscopic hepatectomy is a minimally invasive surgical procedure to remove part of the liver in cases of benign and/or malignant tumors of the organ. Patients benefit from all the advantages of laparoscopic surgery, such as faster recovery, minimal pain, and smaller surgical wounds, compared to open surgery.
Lei ZL et al. in their study entitled “Comparison of the efficacy of laparoscopic hepatectomy and radiofrequency ablation for small hepatocellular carcinoma: A retrospective study. World J Gastroenterol 2025; 31(45): 111540 demonstrated that, in patients with small hepatocellular carcinoma, laparoscopic hepatectomy significantly prolongs survival compared with tumor destruction. The findings suggest that laparoscopic hepatectomy should be preferred in these patients, provided liver function is adequate. Nevertheless, radiofrequency tumor destruction remains a valuable weapon in our pharmaceutical arsenal, especially in patients at high surgical risk. It is understandable, however, that these surgical procedures must be performed in specialized centers by surgeons with extensive experience in laparoscopic surgery, particularly in liver surgery."
[Collapse]
Lei ZL, Tan ZL, Luo YH, Yang M, Wang JL, Qin Z, Liu YY. Comparison of the efficacy of laparoscopic hepatectomy and radiofrequency ablation for small hepatocellular carcinoma: A retrospective study. World J Gastroenterol 2025; 31(45): 111540
15
"This mechanism showed an understanding of mechanisms. As a review article, it includes important information about obesity. Figures ..."
[Read more]
"This mechanism showed an understanding of mechanisms. As a review article, it includes important information about obesity. Figures 1 and 2 were well designed. The therapeutic strategies in Table 1 also included important information. The authors are urged to perform research work on the subject area of this manuscript, especially the concept of the therapeutic strategy.
"
[Collapse]
Chen KR, Chen ZY, Liu FY, Xie CY, Hu J, Wang SY, Xu B, Xu TC. Macrophage-mediated metabolic dysregulation in the pancreas: Insights from obesity. World J Biol Chem 2025; 16(4): 109509
16
"This study analyzes RSPO3 rearrangements in advanced colorectal cancer (aCRC) and their clinical implications. Among 73 patients with ..."
[Read more]
"This study analyzes RSPO3 rearrangements in advanced colorectal cancer (aCRC) and their clinical implications. Among 73 patients with stage pT4a‑b tumors, RSPO3 fusions were detected in 8% of cases, predominantly in right‑sided or transverse colon cancers. These rearrangements were associated with smaller tumor size, normal carcinoembryonic antigen levels, microsatellite stability, and significantly poorer overall survival. The authors also confirmed through in silico analyses that elevated RSPO3 expression correlates with worse recurrence‑free and overall survival in independent CRC cohorts. Strengths of the work include comprehensive next‑generation sequencing of 50 cancer‑related genes, detailed clonal evolution analysis, and integration of clinical, pathological, and molecular data. Overall, the study highlights RSPO3 fusions as a potential prognostic biomarker and therapeutic target in advanced colorectal cancer."
[Collapse]
Tur R, Abad M, Filipovich E, Rivas MB, Rodriguez M, Montero JC, Sayagués JM. RSPO3 rearrangements in advanced colorectal cancer patients and their relationship with disease characteristics. World J Gastrointest Oncol 2025; 17(11): 112838
17
"This retrospective study develops and validates a novel nomogram model to predict survival outcomes in advanced HER‑2 negative gastric ..."
[Read more]
"This retrospective study develops and validates a novel nomogram model to predict survival outcomes in advanced HER‑2 negative gastric cancer patients treated with immunochemotherapy. Using data from 200 patients who received sintilimab plus chemotherapy, the authors identified PD‑L1 expression, microsatellite status, TNM stage, tumor differentiation, neutrophil‑to‑lymphocyte ratio, and the C‑reactive protein–albumin–lymphocyte (CALLY) index as independent prognostic factors. The resulting models demonstrated strong discrimination (C‑index 0.78–0.82) and calibration, with high accuracy for progression‑free and overall survival across multiple time points. Strengths of the work include integration of molecular, clinical, and inflammatory markers into a single predictive tool, rigorous statistical validation, and clear demonstration of clinical applicability. Overall, the study provides a robust framework for individualized risk assessment and treatment planning in HER‑2 negative advanced gastric cancer."
[Collapse]
Yao ZY, Bao G, Li GC, Hao QL, Ma LJ, Rao YX, Xu K, Ma X, Han ZX. Survival prognosis in advanced HER-2 negative gastric cancer treated with immunochemotherapy: A novel model. World J Gastrointest Oncol 2025; 17(11): 112981
18
"This meta‑analysis evaluates the efficacy of neoadjuvant immunotherapy combined with radiotherapy and chemotherapy in locally advanced ..."
[Read more]
"This meta‑analysis evaluates the efficacy of neoadjuvant immunotherapy combined with radiotherapy and chemotherapy in locally advanced rectal cancer (LARC). Across 15 studies involving 796 patients, the addition of immunotherapy significantly improved major pathological response, pathological complete response, and clinical complete response, particularly in patients with proficient mismatch repair (pMMR) and microsatellite stability. Rates of R0 resection and sphincter‑preserving surgery were also higher, while adverse events such as hematologic toxicity and liver dysfunction remained within acceptable limits. Strengths of the study include comprehensive literature retrieval, rigorous subgroup and sensitivity analyses, and clear reporting of heterogeneity and publication bias. Overall, the findings suggest that integrating immunotherapy into neoadjuvant chemoradiotherapy regimens enhances remission and organ preservation without substantially increasing complications, supporting its consideration as a first‑line strategy for LARC."
[Collapse]
Yan WX, Yuan HQ, Xiong ZY, Qin LJ, Wu J, He J, Mu J, Li J, Li N. Meta-analysis of the efficacy of neoadjuvant immunotherapy combined with radiotherapy and chemotherapy for locally advanced rectal cancer. World J Gastrointest Oncol 2025; 17(11): 113048
19
"This study investigates folate receptor–positive circulating tumor cells (FR+ CTCs) as potential biomarkers for hepatocellular ..."
[Read more]
"This study investigates folate receptor–positive circulating tumor cells (FR+ CTCs) as potential biomarkers for hepatocellular carcinoma (HCC). In a retrospective cohort of 128 patients, FR+ CTC counts demonstrated superior diagnostic accuracy compared to alpha‑fetoprotein (AFP), with sensitivity of 90% and specificity of 77%. Elevated FR+ CTC levels correlated with adverse pathological features such as larger tumor size, multiple lesions, macrovascular invasion, and extrahepatic metastasis. Importantly, higher baseline FR+ CTC counts predicted shorter disease‑free survival after hepatectomy, with a cutoff of 12.9 FU/3 mL distinguishing high‑risk patients. Strengths of the work include rigorous methodology using ligand‑target PCR, clear statistical validation with ROC and Cox regression analyses, and demonstration that FR+ CTCs may serve both diagnostic and prognostic roles independent of AFP. These findings provide promising evidence that FR+ CTC quantification could enhance patient stratification, guide treatment evaluation, and improve recurrence prediction in HCC."
[Collapse]
Zhang ZY, Zhou M, Liu JJ, Zhang W. Folate receptor-positive circulating tumor cells might function as potential biomarkers for hepatocellular carcinoma. World J Gastrointest Oncol 2025; 17(11): 113431
20
"This article presents two rare case reports of gastrointestinal stromal tumors (GISTs) driven by novel FGFR2 fusions, expanding the ..."
[Read more]
"This article presents two rare case reports of gastrointestinal stromal tumors (GISTs) driven by novel FGFR2 fusions, expanding the molecular spectrum beyond the well‑known KIT and PDGFRA mutations. Both patients underwent successful surgical resection followed by adjuvant imatinib therapy, achieving sustained remission over more than two years. The study is well executed in several respects: it highlights the importance of comprehensive genomic profiling with next‑generation sequencing to uncover actionable mutations, demonstrates that even non‑canonical alterations may respond to standard tyrosine kinase inhibitors, and underscores the potential of FGFR‑targeted therapies for imatinib‑resistant or advanced disease. By carefully documenting clinical, pathological, and molecular features, the authors provide valuable preliminary evidence that FGFR2 fusions may define a distinct, therapeutically relevant GIST subtype."
[Collapse]
Hong YY, Shou CH, Yang WL, Wang XD, Zhang Q, Liu XS, Yu JR. FGFR2 fusions as novel oncogenic drivers in gastrointestinal stromal tumors: Two case reports and review of literature. World J Gastrointest Oncol 2025; 17(11): 113262
15875 items Read more >>
Peer-Reviewers and Manuscript Statistics
- Editorial board members
- 2264
- Peer-reviewers
- 35090
- Manuscripts received today
- 13
- Manuscript reviews today
- 31
- Unhandled manuscripts today
- 201
- Active peer-reviewers today
- 2140
- Reviewer acceptance today
- 20
- Reviewer refusals today
- 57
- Total accepted manuscripts
- 39056
- Total rejected manuscripts
- 44001
- Total peer-reviewers
- 4566681
- Total submissions
- 37029
1
2025-12-20 | Browse: 5827 | Download: 356
2
2025-12-20 | Browse: 6036 | Download: 523
3
4
2025-12-20 | Browse: 4654 | Download: 348
5
2025-12-20 | Browse: 5373 | Download: 399
6
7
8
9
2025-12-20 | Browse: 5441 | Download: 422
10
11
12
2025-12-20 | Browse: 4672 | Download: 423
13
14
15
16
17
2025-12-20 | Browse: 5392 | Download: 400
18
19
20
2025-12-20 | Browse: 4387 | Download: 326
61232 items Read more >>
1
2
3
2025-12-11 | Browse: 25 | Download: 76
4
2025-12-11 | Browse: 24 | Download: 43
5
6
2025-12-10 | Browse: 40 | Download: 101
7
8
9
10
11
12
13
14
15
2025-12-05 | Browse: 43 | Download: 79
16
17
18
19
20
10172 items Read more >>
73975 items Read more >>
1
"This minireview systematically synthesizes the intricate interplay between depression and gastric cancer (GC), incorporating ..."
[Read more]
"This minireview systematically synthesizes the intricate interplay between depression and gastric cancer (GC), incorporating neuroendocrine, immunological, and psychosocial mechanisms. The authors effectively underscore the bidirectional causality supported by 52 referenced studies, in alignment with the biopsychosocial model. Nonetheless, there are opportunities to enhance methodological rigor and visual communication. Although Figure 1 delineates key components of the bidirectional relationship, its informational density is suboptimal. The figure lacks a hierarchical structuring of pathways (e.g., neuroendocrine versus immune mechanisms) and does not quantify effect sizes (e.g., hazard ratios from cited meta-analyses). It is recommended to incorporate a summary table for comparison. "
[Collapse]
Chen Z, Gong TJ, Zhao L. Bidirectional relationship between depression and the risk and prognosis of gastric cancer. World J Gastrointest Oncol 2025; 17(12): 113272
2
"I want to congratulate the authors, Zhang et al, for conducting a study and identifying the predictors of refractory GERD. They have ..."
[Read more]
"I want to congratulate the authors, Zhang et al, for conducting a study and identifying the predictors of refractory GERD. They have identified the disease duration and anxiety as significant risk factors and at least 90 minutes of moderate-intensity physical activity per week as a protective factor for refractory GERD. One of the important findings in this study is the association of significant Overlap DGBI symptoms (such as dyspepsia, constipation, and diarrhoea) in at least 50% of GERD patients. Since most patients had a duration of illness of more than 4 years, complications of GERD and their comparison between the groups were not noted in this study (a limitation). Although hydrogen impedance is used for diagnosis, the comparison of impedance parameters is not provided. H pylori infection is a protective factor for GERD/Barrett's, which is also a limitation. This study has provided a meaningful conclusion regarding the association between long-term symptoms and refractoriness. "
[Collapse]
Zhang N, Wang Y, Fang SS, Han M, Zheng QW, Zhu YY, Zhang MY, Li JJ, Cui LX, Tian JL, Deng YH, Zhu SL, Ni HM, Zhou L, Zuo GL, Huang TS, Liao Q, Li XQ, Shang YY, Wang YJ, Tian Y, Ge LY, Han HQ, Hu WM, Jiang Y, Li YJ, Mao X, Yang LH, Yao JM, Zheng X, Wang HW, Fang SQ. Clinical characteristics and risk factors of refractory gastroesophageal reflux disease: A multicenter cross-sectional study. World J Gastroenterol 2025; 31(45): 113060
3
"The present Letter provides a concise academic response to the article identified by Reader’s code 05354032. The comments focus on ..."
[Read more]
"The present Letter provides a concise academic response to the article identified by Reader’s code 05354032. The comments focus on several important aspects of the study, including its methodological design, data interpretation, and clinical applicability. The aim is to offer constructive perspectives that may help clarify key issues and support future improvements in related research. "
[Collapse]
Ardila CM, Ángel-Estrada S, González-Arroyave D. Robot-assisted vs conventional lumbar interbody fusion: A systematic review and meta-analysis of perioperative, radiographic, and clinical outcomes. World J Orthop 2025; 16(11): 110276
4
"The study title "Comparison of the efficacy of laparoscopic hepatectomy and radiofrequency ablation for small hepatocellular ..."
[Read more]
"The study title "Comparison of the efficacy of laparoscopic hepatectomy and radiofrequency ablation for small hepatocellular carcinoma: A retrospective study" by Lei et al. aims to compare the long-term survival and perioperative outcomes of Laparoscopic hepatectomy (LH) and radiofrequency ablation (RFA) for small hepatocellular carcinoma (HCC). This retrospective study included 254 patients with small HCC who were collected from Hospital of Chongqing Medical University between December 2022 and March 2025. The results showed that LH was associated with longer operative time, greater blood loss, prolonged recovery, higher costs, and increased complication rates. Consequently, LH, though associated with increased perioperative morbidity, provides superior long-term survival outcomes compared with RFA in patients with small HCC. This study had many limitations such as potential for selection bias and confounding factors that were not controlled for is inherent. The decision to undergo either LH or RFA was made based on clinical judgment and patient-specific factors, which could introduce bias. The sample size was still be insufficient to detect subtle differences in outcomes between the two modalities, especially for subgroups with specific tumor characteristics or comorbidities. Moreover, LH and RFA techniques have evolved over time, and variations in operator experience and institutional protocols could influence outcomes. "
[Collapse]
Lei ZL, Tan ZL, Luo YH, Yang M, Wang JL, Qin Z, Liu YY. Comparison of the efficacy of laparoscopic hepatectomy and radiofrequency ablation for small hepatocellular carcinoma: A retrospective study. World J Gastroenterol 2025; 31(45): 111540
5
"We are delighted to read the high-quality review by Zheng et al[1], published in the World Journal of Gastroenterology, which offers ..."
[Read more]
"We are delighted to read the high-quality review by Zheng et al[1], published in the World Journal of Gastroenterology, which offers insightful perspectives on the neuroimmune mechanisms contributing to the pathogenesis of inflammatory bowel disease (IBD). The intricate interplay between the autonomic nervous system (ANS) and the immune response, particularly involving vagus nerve stimulation (VNS) and its effects on macrophages, provides a promising avenue for future therapeutic interventions in IBD. The review underscores the emerging concept of neuroimmune interactions, particularly the cholinergic anti-inflammatory pathway (CAIP), which regulates inflammation through the vagus nerve and its interaction with intestinal macrophages. This is an exciting area of research, especially in the context of IBD, where inflammation is at the heart of the disease's pathology. Macrophages, as highlighted in the review, play a crucial role in maintaining intestinal homeostasis, but when overactivated, they contribute to the excessive production of proinflammatory cytokines, exacerbating the condition. This review draws attention to how the cholinergic system can modulate macrophage activity, reducing the inflammatory burden through the activation of the α7 nicotinic acetylcholine receptor (α7nAChR). The role of VNS as an approach to activate the cholinergic pathway and regulate inflammation in IBD is a breakthrough concept. Studies showing the beneficial effects of VNS in reducing inflammation and enhancing immune tolerance are promising, offering a potential alternative to conventional treatments, especially in patients with refractory IBD. Furthermore, the use of VNS to modulate the autonomic nervous system offers a unique therapeutic strategy for restoring balance between sympathetic and parasympathetic tones in patients, whose autonomic dysfunction may contribute to disease exacerbation. While the current data on VNS in IBD are promising, the review rightly calls for further research to better establish the clinical applicability of VNS, especially through non-invasive techniques such as transauricular and transcervical VNS. These methods, as highlighted, may offer a safer and more accessible alternative to invasive VNS, which has shown positive effects in treating other inflammatory conditions. The ongoing exploration of VNS in clinical trials, coupled with advancements in understanding the mechanisms of cholinergic signaling in immune cells, opens new avenues for therapeutic interventions in chronic inflammatory diseases. However, as the review mentions, there are still challenges that need to be addressed. The precise mechanisms through which VNS modulates immune responses, particularly in macrophages, are still under investigation. Additionally, while VNS has shown potential in preclinical models, there is a need for larger, well-designed clinical studies to confirm the safety, efficacy, and long-term benefits of VNS in IBD patients. The heterogeneity of IBD, along with differences in patient responses to treatment, further complicates the development of standardized protocols for VNS treatment. In conclusion, the review provides an excellent overview of the current state of research on neuroimmune interactions in IBD, with a special focus on the potential of VNS as a novel therapeutic strategy. The integration of neuroimmune regulation, particularly through the cholinergic pathway, into the treatment of IBD represents an innovative approach that could offer significant improvements in patient outcomes. As we move forward, I hope that the continued research in this field will provide more concrete evidence to support the use of VNS in clinical practice, potentially offering a transformative treatment for IBD patients who have not responded to traditional therapies. LIMITATIONS OF THE REVIEW While the review provides a comprehensive overview of the potential therapeutic role of vagus nerve stimulation (VNS) in inflammatory bowel disease (IBD), there are some limitations that should be addressed in future research. First, while the article highlights the promising effects of VNS, particularly through the cholinergic anti-inflammatory pathway (CAIP), there is a lack of in-depth discussion regarding the specific cellular mechanisms involved. The exact signaling pathways through which VNS modulates macrophage activity and alters immune responses remain unclear, and more detailed mechanistic studies are needed to provide a clearer understanding. Additionally, the review does not fully address the challenges associated with the translation of VNS into clinical practice. For instance, the variability in patient response to VNS, the optimal stimulation parameters (e.g., frequency, duration, and intensity), and the potential side effects of VNS, particularly in IBD patients with coexisting conditions, are aspects that require more attention. Lastly, the review focuses primarily on the autonomic nervous system's role in IBD, but it overlooks other possible neuroimmune interactions that could also influence disease progression. A broader exploration of how other neural pathways or neuropeptides contribute to IBD would provide a more comprehensive view of the neuroimmune mechanisms at play. CONCLUSION The review provides an insightful exploration of the neuroimmune mechanisms involved in inflammatory bowel disease (IBD), particularly focusing on the role of intestinal macrophages and the cholinergic anti-inflammatory pathway. Vagus nerve stimulation (VNS) represents a promising non-invasive therapeutic approach for modulating the immune system and controlling inflammation in IBD. However, further research is needed to fully understand the mechanisms behind VNS and to establish its efficacy in clinical settings for treating chronic inflammatory diseases such as IBD. With the development of non-invasive VNS technologies, future therapies may offer safer and more effective treatments for patients suffering from IBD. "
[Collapse]
Zheng L, Duan SL. Neuroimmune interactions in inflammatory bowel disease: Role of intestinal macrophages and the cholinergic pathway. World J Gastroenterol 2025; 31(44): 109440
6
"This editorial provides a comprehensive and insightful overview of self-expandable metal stents (SEMS) in acute colonic obstruction, ..."
[Read more]
"This editorial provides a comprehensive and insightful overview of self-expandable metal stents (SEMS) in acute colonic obstruction, standing out for its clinical relevance and systematic organization. The authors adeptly synthesize cutting-edge techniques (e.g., fluoroscopy-free stenting, two-person colonoscopy) and critical considerations like stent design selection, backed by high-quality recent evidence, which offers valuable guidance for clinical practice. The discussion of complications and mitigation strategies is pragmatic, while the exploration of future directions (e.g., zero-border stents, multidisciplinary collaboration) reflects a forward-thinking perspective. The academic expression is precise and fluent, with consistent use of professional terminology and clear logical progression. A minor suggestion is to include brief comparative data on cost-effectiveness among different stenting techniques or stent types, which would further assist healthcare institutions in decision-making. Overall, this is a high-quality, clinically impactful piece that serves as an excellent reference for gastroenterologists and surgeons specializing in colorectal disorders. "
[Collapse]
Sun HY, Li ZC, Wang HL. Current mechanisms and techniques for placement of self-expandable metal stents in acute colonic obstruction. World J Gastrointest Surg 2025; 17(11): 110512
7
"The editorial authored by Watanabe presents a timely and clinically pertinent overview of lisocabtagene maraleucel (liso-cel) CAR-T ..."
[Read more]
"The editorial authored by Watanabe presents a timely and clinically pertinent overview of lisocabtagene maraleucel (liso-cel) CAR-T therapy, specifically addressing nodal and gastrointestinal follicular lymphoma (GI-FL). The author skillfully amalgamates essential findings from the TRANSCEND FL trial, emphasizing the extraordinary 97% overall response rate and a 94% complete response rate, alongside a notably reduced toxicity profile where grade ≥3 cytokine release syndrome (CRS) was absent, and grade ≥3 neurotoxicity was observed in merely 3% of patients. This concentrated analysis on the unique advantages of liso-cel—particularly its defined CD4+/CD8+ composition and the feasibility of outpatient treatment—addresses a significant void in the existing literature, especially in light of the historical exclusion of GI-FL from crucial CAR-T trials. The comparative framework juxtaposing lisocabtagene maraleucel with axicabtagene ciloleucel and tisagenlecleucel provides invaluable insights for clinical decision-making. Nevertheless, the editorial's otherwise robust examination fails to explore subtleties regarding the durability of response in high-risk subpopulations. Although the reported 12-month progression-free survival rate exceeding 85% is promising, emerging data indicate that follicular lymphoma patients with specific genomic alterations (e.g., TP53 mutations or 1p36 deletions) display varied responsiveness to CAR-T therapy. This omission is particularly salient for GI-FL, where the biological characteristics of the disease may diverge from those of nodal FL due to influences from the microenvironment. Furthermore, the editorial rightly recognizes cost as a barrier but insufficiently emphasizes how the manufacturing logistics of Liso-Cel disproportionately hinder accessibility in advanced GI-FL cases. Unlike nodal FL, where treatment delays may be manageable, GI-FL frequently presents urgent complications necessitating swift intervention. The three-week manufacturing timeline for liso-cel—despite improvements over previous platforms—remains a challenge for these patients, a difficulty exacerbated by the absence of validated bridging strategies tailored to gastrointestinal involvement. Looking ahead, the integration of endoscopic and molecular staging systems (e.g., Paris classification) with CAR-T therapy response biomarkers emerges as a critical research priority. Real-world studies should specifically investigate GI-FL cohorts to ascertain whether mucosal disease localization influences CAR-T trafficking or persistence. Additionally, the formulation of risk-adapted conditioning regimens could optimize the therapeutic index in patients with gastrointestinal involvement, where organ-specific toxicities remain inadequately characterized. Watanabe's appeal for multicenter collaboration should explicitly encompass these mechanistic and health-services research inquiries to propel personalized CAR-T applications across follicular lymphoma subtypes. "
[Collapse]
Watanabe T. Emerging role of lisocabtagene maraleucel chimeric antigen receptor-T cell in nodal and gastrointestinal follicular lymphoma. World J Gastroenterol 2025; 31(45): 112336
8
"This review elevates our understanding of acetaminophen (APAP)-induced acute liver injury from a “single toxic metabolite acting on ..."
[Read more]
"This review elevates our understanding of acetaminophen (APAP)-induced acute liver injury from a “single toxic metabolite acting on hepatocytes” model to a dynamic network involving multiple hepatic cell populations. Second, it clearly maps out current and potential therapeutic targets, essentially providing a “cell-type–oriented treatment roadmap” for future translational work. The discussion of CYP2E1/CYP3A4, species differences, and risk factors (such as alcohol use, malnutrition, underlying liver disease, and concomitant enzyme-inducing drugs) helps clinicians better identify high-risk populations and appreciate the limitations of extrapolating from animal models, thereby supporting more individualized risk assessment and dosing. In the treatment section, the authors extend beyond the classical “N-acetylcysteine golden window” and cover emerging strategies such as inhibition of NAPQI formation (e.g. fomepizole), mitochondria-targeted antioxidants (Mito-Tempo, MitoQ), modulation of ferroptosis/ferritinophagy, NLRP3–STING inflammasome pathways, as well as cell-based and hepatocyte transplantation therapies. This allows clinical readers to quickly grasp potential combination or alternative approaches that are entering or approaching clinical trials, while signaling to basic scientists multiple promising cellular pathways and targets for deeper exploration. Overall, the article reads as an up-to-date progress review on the multicellular mechanisms and therapeutic targets of APAP-induced acute liver injury, offering both mechanistic clarity and topic inspiration for those working on drug-induced liver injury, emergency/critical care, and liver transplantation—while also realistically emphasizing that most of the evidence remains at the experimental or early translational stage and is not yet ready to change clinical guidelines. "
[Collapse]
Yang D, Kim B, Kim JW. Mechanistic insights into hepatic cell type-specific contributions to acetaminophen-induced acute liver injury. World J Gastroenterol 2025; 31(45): 112720
9
"this review provides a clear and systematic overview of the interactions among intestinal macrophages, the enteric nervous system, ..."
[Read more]
"this review provides a clear and systematic overview of the interactions among intestinal macrophages, the enteric nervous system, and the cholinergic anti-inflammatory pathway in inflammatory bowel disease (IBD). By closely linking basic mechanistic insights with the potential clinical application of vagus nerve stimulation (VNS)—especially low-frequency, non-invasive VNS—the paper offers a fresh “neuroregulation–immune modulation” angle on IBD treatment, which is currently dominated by immunosuppressants and biologics. In terms of clinical practicality, the authors emphasize the promise of non-invasive VNS as a safer and more tolerable approach, while frankly acknowledging that current evidence still largely comes from animal models and a few pilot clinical studies, with a lack of large-scale randomized controlled trials. This “promising yet cautious” tone is valuable for clinical readers. On the one hand, the paper helps gastroenterologists and basic scientists understand why heart rate variability (HRV), emotional status, and autonomic imbalance may be linked to IBD course and relapse; on the other hand, it reminds readers that VNS and α7nAChR-targeted agents are still at the stages of proof-of-concept and early translation. In the short term, their main value lies in inspiring new research designs (for example, clinical trials stratified by HRV, combined with intestinal macrophage phenotype analysis), rather than immediately changing standard treatment pathways. Overall, this work reads like a forward-looking “blueprint” for neuro-immune therapies in IBD and is particularly thought-provoking for readers interested in IBD mechanisms and novel therapeutic strategies. "
[Collapse]
Zheng L, Duan SL. Neuroimmune interactions in inflammatory bowel disease: Role of intestinal macrophages and the cholinergic pathway. World J Gastroenterol 2025; 31(44): 109440
10
"Commentary on "Large Language Models and Large Concept Models in Radiology: Present Challenges, Future Directions, and Critical ..."
[Read more]
"Commentary on "Large Language Models and Large Concept Models in Radiology: Present Challenges, Future Directions, and Critical Perspectives" The transition from LLMs to LCMs, aiming for enhanced semantic reasoning, is fundamentally challenged by the necessity of building these sophisticated models upon historical data streams polluted by human cognitive biases [1]. Diagnostic interpretation errors are often not perceptual misses but interpretive errors driven by faulty reasoning [2,3]. These biases include Anchoring Bias, where a radiologist becomes fixated on an initial impression despite contradictory evidence, often coupled with Confirmation Bias, the inclination to seek information only to affirm that initial theory [2,4,5]. Similarly, Availability Bias, or availability heuristics, predisposes the interpreter to recall recently seen or memorable diagnoses regardless of the actual prevalence [3,4,6]. When AI learns its "concepts" or "relationships" from millions of reports generated under the influence of these specific biases, it may normalize or amplify flawed reasoning patterns, potentially leading to widespread, systemic diagnostic vulnerabilities that mirror rather than correct human limitations [3]. For instance, an AI trained primarily on reports that exhibit Zebra Retreat—the avoidance of accurate but rare diagnoses due to lack of confidence—will systematically underreport uncommon but critical findings, reducing the diagnostic sensitivity for edge cases [2,6]. The core strength of future AI systems must therefore lie not just in conceptual depth but in active debiasing, mitigating the human errors that underpin the training corpus [4,5]. If AI recommendations are opaque, clinicians may fall prey to Blind Obedience or Premature Closure by accepting the machine's initial diagnosis without critical Type 2 analysis [2,6]. To counter this, AI must incorporate the same cognitive forcing strategies used by human interpreters, demanding metacognition ("thinking about thinking") to identify susceptibility to bias [3,4]. Furthermore, AI must specifically address the Hindsight Bias that plagues retrospective quality review [2,6], by ensuring its decision pathways are fully auditable and transparent, allowing for objective assessment of whether an error resulted from inherent data contamination or algorithmic failure. As AI integrates deeper into clinical workflows, its ability to enhance safety hinges on proactively resisting the transfer and propagation of predictable human cognitive limitations [6]. References 1. Merchant SA, Merchant N, Varghese SL, Shaikh MJS. Large language models and large concept models in radiology: Present challenges, future directions, and critical perspectives. World J Radiol. 2025;17(11):114754. [DOI: 10.4329/wjr.v17.i11.114754] 2. Onder O, Yarasir Y, Azizova A, Durhan G, Onur MR, Ariyurek OM. Errors, discrepancies and underlying bias in radiology with case examples: a pictorial review. Insights Imaging. 2021;12:51. [PMID: 33877458. DOI: 10.1186/s13244-021-00986-8] 3. Chen J, Gandomkar Z, Reed WM. Investigating the impact of cognitive biases in radiologists' image interpretation: A scoping review. Eur J Radiol. 2023;166:111013. [PMID: 37541180. DOI: 10.1016/j.ejrad.2023.111013] 4. Busby LP, Courtier JL, Glastonbury CM. Bias in Radiology: The How and Why of Misses and Misinterpretations. Radiographics. 2018;38:236–247. [PMID: 29194009. DOI: 10.1148/rg.2018170107] 5. Gunderman RB. Biases in radiologic reasoning. AJR Am J Roentgenol. 2009;192:561–564. [PMID: 19234247. DOI: 10.2214/AJR.08.1220] 6. Yoon SY, Lee KS, Bezuidenhout AF, Kruskal JB. Spectrum of Cognitive Biases in Diagnostic Radiology. Radiographics. 2024;44:e230059. [PMID: 38843094. DOI: 10.1148/rg.230059] "
[Collapse]
Merchant SA, Merchant N, Varghese SL, Shaikh MJS. Large language models and large concept models in radiology: Present challenges, future directions, and critical perspectives. World J Radiol 2025; 17(11): 114754
11
"The authors present a clinically important case highlighting the coexistence of mixed connective tissue disease (MCTD) and ..."
[Read more]
"The authors present a clinically important case highlighting the coexistence of mixed connective tissue disease (MCTD) and tuberculosis (TB), a scenario that poses substantial diagnostic challenges in TB-endemic regions. The manuscript is well structured and clearly describes the sequence of clinical events, laboratory workup, and therapeutic decisions. The discussion appropriately emphasizes the overlap between autoimmune manifestations and infectious etiologies, particularly when both present with pulmonary involvement. From an academic standpoint, the case is relevant and contributes meaningfully to the limited global literature examining MCTD–TB coexistence. The authors successfully integrate immunological findings with epidemiological considerations, underscoring the need for high clinical suspicion and comprehensive autoimmune evaluation in complex presentations. The reference list is current and well selected, drawing from both rheumatology and infectious disease literature. The language is generally clear and understandable, although a few sections may benefit from stylistic tightening to improve flow, particularly in the discussion where multiple concepts are presented in close succession. Minor grammatical refinements could enhance readability. The inclusion of comprehensive tables and immunological profiles strengthens the diagnostic clarity of the case. For future research and case documentation, the authors may consider: 1. Providing a more detailed longitudinal follow-up, especially regarding TB status, autoimmune markers, and treatment tapering, as long-term outcomes for MCTD-TB coexistence are not well described in the literature. 2. Elaborating on radiologic findings, given the central role of imaging in differentiating pulmonary TB from autoimmune lung involvement. 3. Discussing possible immunopathological links between chronic infections and autoimmune flare, which could enrich the mechanistic understanding of such overlap syndromes. 4. Addressing medication safety monitoring, particularly concerning hepatotoxicity in the context of ATT combined with corticosteroids and hydroxychloroquine. Overall, this is a valuable clinical contribution that highlights key diagnostic considerations in resource-limited, TB-endemic settings. The manuscript is academically sound, clinically relevant, and will be informative for physicians managing complex autoimmune presentations. "
[Collapse]
Sial F, Basit A, Ghafoor N, Sial W, Basil AM. Mixed connective tissue disease and tuberculosis coexistence as a diagnostic dilemma: A case report. World J Clin Cases 2025; 13(33): 109866
12
"The review by Nian et al. offers a thorough and thoughtfully articulated overview of current insights into Osteopontin (OPN)–mediated ..."
[Read more]
"The review by Nian et al. offers a thorough and thoughtfully articulated overview of current insights into Osteopontin (OPN)–mediated PI3K/AKT signaling and its pivotal influence on gastrointestinal cancer progression, metastatic behavior, and therapeutic resistance. The authors skillfully synthesize mechanistic and translational findings, underscoring how OPN-driven activation of the PI3K/AKT pathway promotes epithelial–mesenchymal transition, metabolic adaptation, immune escape, and chemoresistance. Their discussion of OPN splice variants, tumor microenvironment interactions, and biomarker-informed therapeutic strategies provides meaningful guidance for advancing precision oncology. A major strength of the review is its emphasis on the inherent complexity and compensatory nature of OPN–PI3K/AKT signaling, which helps explain the challenges associated with single-agent therapeutic approaches. The recommendation to pursue combination strategies—such as pairing PI3K/AKT inhibitors with immune checkpoint blockade or OPN-targeted antibodies—is timely and supported by accumulating preclinical data. Furthermore, the manuscript’s focus on PIK3CA mutation subsets and OPN expression as potential predictive biomarkers may enable more refined patient stratification in future clinical trials. Despite these promising avenues, clinical translation remains constrained. Current trials evaluating PI3K/AKT inhibitors in gastrointestinal malignancies have yielded limited efficacy and notable toxicity, highlighting the need for more rigorous biomarker-driven study designs. Although the review acknowledges these issues, a deeper appraisal of the reasons underlying clinical shortcomings—and the specific contribution of OPN signaling to these obstacles—would further strengthen its clinical impact. In sum, this review provides a valuable contribution by elucidating the diverse oncogenic roles of OPN and outlining strategic paths toward overcoming therapeutic resistance. Continued research into isoform-specific activity, tumor microenvironmental dynamics, and rational combinatorial regimens will be crucial for realizing the therapeutic potential of targeting the OPN–PI3K/AKT axis in gastrointestinal cancers. "
[Collapse]
Nian H, Bai Y, Wang HY, Yu H, Zhang ZL, Shi RH, Zhang S, Wu YB, Zhou DH, Du QC. Targeting the Osteopontin-regulated PI3K/AKT signaling pathway: A molecular approach to overcome drug resistance and metastasis in gastrointestinal tumors. World J Gastrointest Oncol 2025; 17(11): 109923
13
"This article presents an interesting retrospective study involving a substantial cohort of patients, highlighting the role of total ..."
[Read more]
"This article presents an interesting retrospective study involving a substantial cohort of patients, highlighting the role of total neoadjuvant therapy (TNT), specifically the RAPIDO protocol, compared to conventional long-course chemoradiotherapy (LCCRT) in the management of locally advanced rectal cancer (LARC). The study focuses on early surgical outcomes, a topic of significant clinical relevance. The cornerstone of LARC treatment remains optimal surgical resection via total mesorectal excision (TME). To reduce locoregional failure, preoperative concurrent chemoradiotherapy has long been the standard of care. However, as noted in the article and supported by prior evidence (e.g., Fokas et al.), the efficacy of this approach is primarily confined to local control, while distant metastases continue to be a major cause of treatment failure and compromised survival. The intensification of neoadjuvant therapy through TNT addresses this limitation by achieving early systemic control, significant tumor downstaging, and higher rates of pathological complete response, all without compromising early surgical outcomes compared to LCCRT, as demonstrated in this study. Moreover, the authors report that TNT is associated with a shorter total stoma duration and a lower permanent stoma rate, which are meaningful benefits for patients' quality of life. Recent landmark trials, such as RAPIDO and PRODIGE 23, have provided robust evidence supporting the use of TNT, showing improved pathological complete response, better treatment compliance, and reduced distant metastases compared to LCCRT. This study adds valuable real-world data to the growing body of literature affirming the safety and feasibility of TNT from a surgical perspective. We commend the authors for their contribution and agree that further prospective studies with longer follow-up are warranted to evaluate long-term oncological outcomes. (By Prof Sanaa El Majjaoui and Pr Nabil Ismaili) "
[Collapse]
Jabbar SAA, Choo ALE, Wong NW, Ngu JCY, Teo NZ. Comparing early surgical outcomes between total neoadjuvant therapy and standard long course chemoradiotherapy for rectal cancer. World J Gastrointest Oncol 2025; 17(11): 111250
14
"This minireview describes the important role of 0steopontin (OPN)-regulated the phosphatidylinositol 3-kinase (PI3K)/protein kinase ..."
[Read more]
"This minireview describes the important role of 0steopontin (OPN)-regulated the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) signaling pathway in gastrointestinal tumor proliferation, metastasis, chemoresistance, and immune evasion. Targeting osteopontin-regulated PI3K/AKT signaling pathway with PI3K/AKT inhibitors or OPN neutralizing antibodies may reverse drug resistance and suppress metastasis. Further research should be needed to find combination therapies which have the potential to provide more effective anti-tumor activity towards refractory cancers. "
[Collapse]
Nian H, Bai Y, Wang HY, Yu H, Zhang ZL, Shi RH, Zhang S, Wu YB, Zhou DH, Du QC. Targeting the Osteopontin-regulated PI3K/AKT signaling pathway: A molecular approach to overcome drug resistance and metastasis in gastrointestinal tumors. World J Gastrointest Oncol 2025; 17(11): 109923
15
"I want to congratulate the authors for conducting this excellent study on the impact of PAD in PEP. This study has demonstrated that ..."
[Read more]
"I want to congratulate the authors for conducting this excellent study on the impact of PAD in PEP. This study has demonstrated that PAD, particularly Type B, has a Significant risk of PEP. This subgroup analysis of PAD is important for advancing efforts to prevent PEP. This study included predominantly older patients, where the prevalence of PAD is higher. Whether the presence of only PAD increases the risk of pancreatitis is still difficult to interpret. As PAD increases the difficulty of CBD cannulation, requiring advanced cannulation techniques which itself may increase the risk of PEP, furthermore indication of ERCP is also analysed in both groups "
[Collapse]
Shu J, Liao YS, Zhang YJ, Zhou WL, Zhang H. Impact of periampullary diverticulum on the incidence of post-endoscopic retrograde cholangiography pancreatitis. World J Gastrointest Endosc 2025; 17(11): 111243
16
"The study by Li Lin et al., “Early vs conventional initiation of adjuvant chemotherapy in advanced gastric cancer: A ..."
[Read more]
"The study by Li Lin et al., “Early vs conventional initiation of adjuvant chemotherapy in advanced gastric cancer: A propensity-matched outcomes study,” addresses a clinically relevant question; however, several issues limit the strength and applicability of its conclusions. First, the analysis does not demonstrate any clear advantage of early versus conventional initiation of adjuvant chemotherapy in terms of either overall survival or disease-free survival. A possible benefit is suggested with respect to the rate of peritoneal recurrence, but this signal is difficult to interpret in the absence of any comparison with currently available intraperitoneal treatment strategies. Moreover, the study does not provide robust selection criteria to clearly identify which patients might be optimal candidates for an earlier initiation of adjuvant therapy. Given the well-known short-term physiological impact of gastrectomy, there is a concrete risk that patients starting chemotherapy very early after surgery may actually receive a suboptimal treatment—most notably through dose reductions—precisely in the first cycles, when dose intensity may be most critical. Finally, the heterogeneity of the adjuvant chemotherapy regimens, which persists even after propensity score matching, further complicates interpretation of the results and limits the ability to draw firm conclusions regarding the true effect of treatment timing per se. "
[Collapse]
Lin L, Zhang P, Wang YY, Cai YF, Wen LB, Chen WP, Xiao YF, Li ZK, Liu GY. Early vs conventional initiation of adjuvant chemotherapy in advanced gastric cancer: A propensity-matched outcomes study. World J Gastroenterol 2025; 31(42): 110069
17
"Long-term prognosis of HBV-cirrhosis hepatocellular carcinoma recurrence and mortality rates post-treatment with antivirals TDF, TAF, ..."
[Read more]
"Long-term prognosis of HBV-cirrhosis hepatocellular carcinoma recurrence and mortality rates post-treatment with antivirals TDF, TAF, ETV and curative radiofrequency ablation is still controversial Dina Johar* Department of Biochemistry and Nutrition, Faculty of Women for Arts, Sciences and Education, Ain Shams University, Heliopolis, Cairo, Egypt *Dina Johar, PhD Department of Biochemistry and Nutrition Faculty of Women for Arts, Sciences, and Education Ain Shams University, Cairo, Egypt Phone:+2 01060782045 Email: dinajohar@gu.edu.eg • To whom correspondence should be addressed Abstract The efficiency of antiviral agents for hepatitis B cirrhosis-related hepatocellular carcinoma (HCC) is still an important clinical challenge with high recurrence rates. In this commentary, we focus on recent findings from Xu et al. We highlight the potential benefit of studying HBV genotypes and subgenotypes as possible mechanisms behind different responses to antivirals. Mechanisms of viral reactivation that parallel HCC recurrence remain uncovered. The commentary is a significant step forward in understanding the nuanced approach to managing HCC recurrence and mortality rate in HBV-cirrhosis patients, offering valuable insights for clinical decision-making. Keywords HBV-related HCC, TDF, TAF, ETV, recurrence, mortality Core Tip A similar virological response to TDF, TAF, and ETV treatment in the first 6-12 months may require further investigation to understand early treatment dynamics. Understanding how HBV genotypes and subgenotypes influence chronic active HBV infection is crucial. Investigating potential molecular mechanisms that explain recurrence rate differences helps develop predictive models for individualized treatment selection. Background The paper entitled “Effect of antiviral therapy on 3-year recurrence and prognosis of hepatocellular carcinoma after curative radiofrequency ablation” by Xu et al. (1) is a robust retrospective cohort study that comprehensively evaluates long-term prognostic effects of advanced nucleos(t)ide analogs (NAs): ETV, TDF, and TAF on HBV-cirrhosis HCC patients post-RFA outcomes. The study identified four independent predictors of post-RFA HCC recurrence. The study findings recommend TDF or TAF as preferred antiviral agents for the long-term management of such patients. The three antiviral agents had a similar impact on the three-year mortality rate. The study used a substantial sample size (n=319) with a follow-up period of 144 weeks, across multiple time points (6, 12, 24, 36 months), although the sample sizes in the TDF (n=76) and TAF (n=52) groups are relatively small. Two of the major determinants of the outcome of chronic HBV infection are the HBV genotypes and subgenotypes. While Xu et al. adhered to established diagnostic guidelines, there are at least ten different confirmed HBV genotypes (A-J). There is limited knowledge about how different genotypes and subgenotypes of HBV affect the risk of HCC recurrence in patients with HBV-cirrhosis related HCC. The best way to find out is through long-term, population-based studies. These studies should compare people with different genotypes and follow them over time. For example, there is a substantial homogeneity of HBV subtypes found in Egypt, a country with a comparably high HBV-cirrhosis-related HCC, mostly genotype D, subgenotype D3, hepatitis B surface antigen (HBsAg) subtype ayw2, with a prevalence of the Major Hydrophilic Region (MHR) mutations (2). Genotype D is related to more advanced liver disease, i.e., HCC, than other genotypes (3) and is an independent risk for Fulminant Hepatitis (FH) (4). Whether new classes of drugs are needed to manage chronic HBV, whether a cure is possible, or even necessary, has not been addressed. The goal of new therapies for chronic hepatitis B should be to achieve a virological cure. Current NAs can slow down HBV replication and help improve liver damage. However, they rarely fully clear chronic HBV infections. There is an urgent need for new drugs and more effective strategies to combat the virus, which eventually will help get rid of the cancer. Still, more research is needed to find clear links between specific genotypes and risks like cirrhosis or HCC. Some research has been carried out in areas such as Asia and Alaska, but many genotypes, including A1 and D, have not been studied in long-term, prospective research. Data is missing for some genotypes and subgenotypes, such as A3, E, F4, and H, regarding their impact on health. Collaboration between multiple institutions from different countries enhances the strength of these studies. Retrospective and prospective studies examined serum HBV DNA levels, liver function, complication rates, and hospital stay duration (5, 6). A study looked at whether high-dose TDF therapy can stop HBV-related HCC recurrence. They designed a study where everyone received the same treatment, with no comparison group. The goal was to determine if using high-dose TDF is practical in real-world settings. They enrolled 10 patients in September 2015 and monitored their progress for three months or until they had to discontinue treatment early. They found that high doses of TDF, up to five times the recommended amount, are poorly tolerated by many patients. These doses also do not effectively stop HBV from replicating as HCC progresses (7). In 2018, a study looked at 607 patients with HBV-related HCC who had surgery or RFA. They divided them into three groups based on their antiviral drugs. The first group, with 261 patients, did not get antiviral treatment. The second group, with 90 patients, received low-strength NAs. The last group, with 256 patients, was treated with high-strength NAs. The main goal was to see how long patients stayed free of cancer recurrence. Patients on ETV and TDF had fewer recurrences than those on other antivirals (8). Another study followed 1,695 patients who had surgery for HBV-related HCC at Korea’s Barcelona Clinic Liver Cancer stage 0 or A between 2010 and 2018. Of these, 813 patients received ETV while 882 took TDF. The study compared cancer recurrence and overall survival between the two groups, using statistical methods to match patients’ backgrounds and adjust for other confounding factors. The analysis started from the day of their liver surgery. Results showed that patients on TDF had a notably lower chance of their HCC recurrence and survived longer overall than those on ETV (9). Between 2013 and 2017, three hospitals enrolled patients with HBV-related HCC who had surgery or ablation as their first treatment. A 421 patients had part of their liver removed, and 305 received RFA. All of these patients started antiviral medication using either ETV or TDF. The study examined HCC recurrence and mortality rates. Researchers adjusted for factors such as HBV DNA levels, tumour characteristics, and patient demographics. The results showed no significant difference in cancer recurrence or death rates between patients treated with ETV and TDF (10). Patients with HCC who go beyond the Milan criteria tend to have a high chance of HCC recurrence post-surgery. When comparing treatments, TDF significantly reduces the risk of HCC recurrence more than ETV therapy (11). Using propensity score matching from the date of liver resection for HCC, TDF showed better overall survival. It also offered stronger protection of liver function. However, in another study, there was no difference in the rate of HCC recurrence between TDF and ETV treatments (12). Other research shows that TDF works better than ETV for eliminating hepatitis B symptoms after RFA treatment. It helps reduce serum HBV DNA levels and improves the albumin-bilirubin (ALBI) grade more effectively (13) (14). A study in 2024 looked at how TDF and ETV affect long-term health in patients with HCC, fatty liver disease, and HBV. The researchers analyzed patient data using a multivariate Cox proportional hazards model and applied a propensity score matching method. They then compared survival outcomes with Kaplan-Meier survival curves. The results showed that TDF helped improve long-term prognosis for patients (15). The latter discovery was confirmed in 2025 in patients with high HBsAg levels after they had their liver removed (16). A study looked back over ten years, finishing in 2025. It included 1,396 patients with HBV-related cirrhotic HCC who had surgery. The patients were divided into two groups: those who took antiviral medicine and those who did not. The research focused on HCC recurrence, taking into account when the antiviral treatment was started, how well the virus was kept under control, and the levels of HBV DNA. Recurrences were labelled as early if they occurred within two years and late if they occurred after that. The study found that long-term antiviral therapy helped prevent late recurrence after surgery, regardless of whether it was started pre- or post-operation. Patients who responded well to the virus treatment saw the biggest benefit (17). Given such controversial results, in Xu et al. study, being a single-center study, there is potential for selection bias inherent in the retrospective study design. The uneven baseline characteristics across treatment groups, potential need for larger sample size to validate findings, and limited exploration of potential mechanisms are behind the differential recurrence rates achieved with TDF, TAF versus ETV, or even behind the similar impact that the three NAs had on the three-year mortality rate. The study will benefit from extending the follow-up period to provide more comprehensive long-term insights. Considering propensity score matching to reduce potential selection bias. Expanding the research scope through multi-center collaborative study enhances external validity and generalizability. Exploring potential interaction effects between NAs and the molecular mechanisms underlying the differential efficacy of TDF and TAF is insightful. Including more diverse patient populations enhances analytical approach, provides a nuanced understanding of anti-HBV agent effectiveness and contributes to a personalized medicine approach in hepatology. Including sensitivity analyses helps validate findings. Declarations Funding This commentary did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. The author declare that no honorarium, grant, or other form of payment was given to anyone to produce the manuscript. Conflict of interest The author declares no conflict of interest exists. Consent to publish Not applicable. Availability of data and materials All data generated or analyzed during this study are included in this published article. Acknowledgment N/A References 1. Xu B, Zhang X, Liu F, Li F, Zhang X, Xiang H, et al. Effect of antiviral therapy on 3-year recurrence and prognosis of hepatocellular carcinoma after curative radiofrequency ablation. World J Gastrointest Oncol 2025;17: 112689. 2. Abu Zeid WA RD, Shemis MA,. Prevalence of mutations within major hydrophilic region of hepatitis B virus and their correlation with genotypes among chronically infected patients in Egypt. Arab Journal of Gastroenterology 2016 17 (2016) 34–40. 3. Thakur V, Guptan RC, Kazim SN, Malhotra V, SK. S. Profile, spectrum and significance of HBV genotypes in chronic liver disease patients in the Indian subcontinent. . J Gastroenterol Hepatol. 2002;17:165-70. 4. Wai CT, Fontana RJ, Polson J, Hussain M, Shakil AO, Han SH, et al. US Acute Liver Failure Study Group. Clinical outcome and virological characteristics of hepatitis B-related acute liver failure in the United States. J Viral Hepat. 2005 12:192-8. 5. Yuan B, Li R, Yuan W, Xiang B, Zheng M, Yang T, et al. Perioperative entecavir for patients with HBV-related hepatocellular carcinoma and low levels of viral DNA: analysis using propensity score matching. Oncotarget. 2017 16(31):51810-6. 6. Yoo S, Jang J, Kwon J, Jung S, Jang B, Choi J. Preemptive antiviral therapy with entecavir can reduce acute deterioration of hepatic function following transarterial chemoembolization. . Clin Mol Hepatol. 2016 22:458-65. 7. Hwang S, Song G, Jung D, Yoon Y, Yoo H, Tak E. High-dose tenofovir is not effective in suppressing hepatitis B virus replication in patients with hepatocellular carcinoma progression: a preliminary result. Korean J Hepatobiliary Pancreat Surg.2016(1). 8. Cho H, Ahn H, Lee DH, Lee JH, Jung YJ, Chang Y, et al. Entecavir and tenofovir reduce hepatitis B virus-related hepatocellular carcinoma recurrence more effectively than other antivirals. . Journal of viral hepatitis. 2018;25:707–17. 9. Choi J, Jo C, Lim YS. Tenofovir Versus Entecavir on Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma After Surgical Resection. Hepatology (Baltimore, Md). 2021 73(661–673). 10. Lee JH, Kim BK, Park SY, Tak WY, Park JY, Kim DY, et al. The efficacies of entecavir and tenofovir in terms of enhancing prognosis after curative treatment of hepatitis B virus-related hepatocellular carcinoma. . Eur J Intern Med.2021:48-55. 11. Shen J, Qi W, Dai J, Leng S, Jiang K, Zhang Y, et al. Tenofovir vs. entecavir on recurrence of hepatitis B virus-related hepatocellular carcinoma beyond Milan criteria after hepatectomy. . Chinese medical journal. 2021;135:301–8. 12. Wang XH, Hu ZL, Fu YZ, Hou JY, Li WX, Zhang YJ, et al. Tenofovir vs. entecavir on prognosis of hepatitis B virus-related hepatocellular carcinoma after curative resection. . Journal of gastroenterology. 2022;57:185–98. 13. Hu Z, Zeng H, Hou J, Wang J, Xu L, Zhang Y, et al. Tenofovir vs. Entecavir on Outcomes of Hepatitis B Virus-Related Hepatocellular Carcinoma after Radiofrequency Ablation. Viruses. 2022;14(656). 14. Giri S, Agrawal D, Afzalpurkar S, Gopan A, Angadi S, Sundaram S. Tenofovir versus entecavir for tertiary prevention of hepatocellular carcinoma in chronic hepatitis B infection after curative therapy: A systematic review and meta-analysis. . Journal of viral hepatitis. 2023;30:108–15. 15. Kong Q GQ, Li W, Chen Z. Effect of tenofovir versus entecavir on the long-term prognosis in hepatocellular carcinoma patients with concurrent metabolic dysfunction-associated steatotic liver disease and hepatitis B. Asian J Surg. 2024 Nov;47(11):4725-4734. doi: 10.1016/j.asjsur.2024.03.147. Epub 2024 Sep 16. PMID: 39289060. 16. Qiu Z XY, Qi W, Shen J, Wen T, Li C. Tenofovir vs Entecavir on the Prognosis of Patients With Hepatitis B Virus-Related Hepatocellular Carcinoma After Liver Resection: The Role of HBsAg Levels. Clin Transl Gastroenterol. 2025 Mar 1;16(3):e00814. doi: 10.14309/ctg.0000000000000814. PMID: 39791573; PMCID: PMC11932590. 17. Liu J BS, Shi X, Yuan T, Yu Y, Lin J, Dai C, Wu Y, Cui L, Zhu B, Fu X, Wang K, Yu W, Li J. Benefits of entecavir therapy in HBV-related hepatocellular carcinoma patients with compensated cirrhosis after hepatectomy: A ten-year retrospective cohort study. Eur J Surg Oncol. 2025 May;51(5):109621. doi: 10.1016/j.ejso.2025.109621. Epub 2025 Jan 23. PMID: 39919509. "
[Collapse]
Xu BG, Zhang X, Liu F, Li FH, Zhang X, Xiang HL, Liang J. Effect of antiviral therapy on 3-year recurrence and prognosis of hepatocellular carcinoma after curative radiofrequency ablation. World J Gastrointest Oncol 2025; 17(11): 112689
18
"This study has provided a combined method including ultrasound and endoscopic examination to present the clinical features of ..."
[Read more]
"This study has provided a combined method including ultrasound and endoscopic examination to present the clinical features of pancreatic cancer in patients with old age. The lifestyles of these patients can be analyzed to perform the potential relationship in the prognosis of pancreatic cancer. In addition, the important features in malignant level as this study displayed may be summarized by author's efforts to indicate significantly and meaningfully in the prognosis of pancreatic cancer in patients. "
[Collapse]
Zignani N, Balzarini M, Dabizzi E, Fracas E, Millefanti L, Segato S, Vecchi M, Cengia G, Missale G, Tontini GE, Moneghini D, Cavallaro F. Endoscopic ultrasound features of pancreatic solid lesions: Descriptive and predictive analysis on a multicenter sample. World J Gastrointest Endosc 2025; 17(11): 112487
19
"The comprehensive review by Professor Elsayed offers a timely and insightful overview of a critical clinical challenge: the management ..."
[Read more]
"The comprehensive review by Professor Elsayed offers a timely and insightful overview of a critical clinical challenge: the management of recurrent hepatocellular carcinoma (RHCC). As a clinician actively managing HCC patients, I find this synthesis of evidence exceptionally valuable. RHCC indeed lacks standardized guidance, and this review effectively consolidates fragmented data across surgical, locoregional, and systemic modalities, offering pragmatic approaches tailored to recurrence patterns (intrahepatic vs. extrahepatic), liver functional reserve, and prior interventions. RHCC complexity demands collaboration between hepatologists, surgeons, interventional radiologists, and oncologists—highlighted here as essential for optimizing outcomes. The candid discussion on limitations—such as the reduced functional liver remnant post-resection/transplant, donor shortages for salvage LT (SLT), and the aggressive biology of RHCC—grounds the review in clinical reality. Coverage of emerging strategies—like combination therapies (TACE + sorafenib), novel ICIs (e.g., atezolizumab/bevacizumab), and AI-driven recurrence prediction—provides hope and direction for ongoing research. While ther are some points for further discussion. In practice, SLT candidates often face adverse factors (e.g., time to recurrence "
[Collapse]
Elsayed MOK. Treatment of recurrent hepatocellular carcinoma: The current standards and future perspectives. World J Gastrointest Oncol 2025; 17(11): 110735
20
"The study provides strong evidence that circulating GDF15 levels are elevated in IBD patients, with a clear correlation to markers ..."
[Read more]
"The study provides strong evidence that circulating GDF15 levels are elevated in IBD patients, with a clear correlation to markers of inflammation and intestinal permeability. This relationship could offer a new avenue for monitoring disease progression and assessing the severity of IBD. The results showing that GDF15 impacts the intestinal barrier function by modulating tight junctions such as ZO-1 and claudin 1 are especially intriguing. From a clinical standpoint, understanding how GDF15 contributes to barrier dysfunction could lead to new therapeutic targets aimed at preventing the "leaky gut" phenomenon, which is a key feature in IBD. One of the most interesting aspects is the suggestion that GDF15 could be a potential biomarker for intestinal permeability, which could be valuable in both clinical diagnosis and disease monitoring. However, as a clinician, I’d like to see more clarity on how these findings might translate into practical treatment strategies. For instance, how could we use this information to develop therapies targeting GDF15 or its signaling pathways in patients with IBD? Additionally, while the in vitro findings are compelling, clinical trials will be essential to confirm whether modulating GDF15 can indeed improve clinical outcomes for IBD patients. "
[Collapse]
Ruiz-Malagón AJ, Herraiz-Vilela M, Serrano-Pino R, García-Ávila P, Díaz- Suárez L, Carmona-Segovia AD, Becerra-Munoz VM, Jiménez-Navarro M, Arranz-Salas I, López-Villodres JA, Fernández-Castañer A, Gutiérrez-Martínez F, Rodríguez-González FJ, Camargo-Camero R, Alcaín-Martínez G, Rodríguez-Díaz C, García-Fuentes E, Sánchez-Quintero MJ, López-Gómez C. Growth differentiation factor 15 alters intestinal barrier and increases permeability: A new molecular target in inflammatory bowel disease. World J Gastroenterol 2025; 31(41): 110955
1115 items Read more >>
- ALL AUTHOR RESOURCES
- Allegations of Misconduct
- Appeals and Complaints
- Article Processing Charge
- Common Usage of Quantities and Units
- Copyright License Agreement
- Create an Account
- Criteria for Authorship
- Ethics Committee of BPG
- Ethics Statements
- Guidelines for Authors
- Journals
- Language Editing Process for Manuscripts Submitted by Non-Native Speakers of English
- Methods of Post-Publication Debate
- Open-Access
- Publication Misconduct
- Quality of Publications
- Steps for Submitting Manuscripts
- Submit a Manuscript
- ALL PEER-REVIEWER RESOURCES
- Manuscript Decision
- Peer-Review Process
- Peer-Reviewer Tracking for Manuscripts
- Reviewer Acknowledgment
- REFERENCE CITATION ANALYSIS
- Find a Category
- Find a Journal
- Find a Scholar
- Find an Academic Assistant
- Find an Article
- Find an Article PDF
- Subscribe
- Today's Articles
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
California Corporate Number: 3537345